General Information of the Protein
Protein ID |
PT01138
|
||||
---|---|---|---|---|---|
Protein Name |
Thymidine kinase, cytosolic
|
||||
Gene Name |
TK1
|
||||
Sequence |
MSCINLPTVLPGSPSKTRGQIQVILGPMFSGKSTELMRRVRRFQIAQYKCLVIKYAKDTRYSSSFCTHDRNTMEALPACLLRDVAQEALGVAVIGIDEGQFFPDIVEFCEAMANAGKTVIVAALDGTFQRKPFGAILNLVPLAESVVKLTAVCMECFREAAYTKRLGTEKEVEVIGGADKYHSVCRLCYFKKASGQPAGPDNKENCPVPGKPGEAVAARKLFAPQQILQCSPAN
Show/Hide
|
||||
Organism |
Homo sapiens, Human
|
||||
Protein Classification |
Enzyme
>
Transferase
|
||||
Function |
Cell-cycle-regulated enzyme of importance in nucleotide metabolism (PubMed:9575153). Catalyzes the first enzymatic step in the salvage pathway converting thymidine into thymidine monophosphate (PubMed:22385435). Transcriptional regulation limits expression to the S phase of the cell cycle and transient expression coincides with the oscillation in the intracellular dTTP concentration (Probable). Also important for the activation of anticancer and antiviral nucleoside analog prodrugs such as 1-b-d-arabinofuranosylcytosine (AraC) and 3c-azido-3c-deoxythymidine (AZT) (PubMed:22385435).
Show/Hide
|
||||
Uniprot ID |
Show/Hide
|
||||
Ensembl ID | |||||
HGNC ID | |||||
Subcellular Location |
Cytoplasm
|
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000057 , Vero
Biochemical Assays
Clinical Information about the Protein
Target 1 ( Thymidine kinase 1 (TK1) )
Target Type | Successful Target | ||||
---|---|---|---|---|---|
Disease | 4 Target-related Diseases | 4 | |||
1 | Acute myeloid leukaemia [ICD-11: 2A60] | ||||
2 | Human immunodeficiency virus infection [ICD-11: 1C62] | ||||
3 | Pancreatic cancer [ICD-11: 2C10] | ||||
4 | Cardiovascular disease [ICD-11: BA00-BE2Z] | ||||
Approved Drug(s) | 2 Approved Drugs | 2 | |||
1 | DEOXYCYTIDINE | Approved | |||
2 | Penciclovir | Approved | |||
Clinical Trial Drug(s) | 2 Clinical Trial Drugs | 2 | |||
1 | RP101 | Phase 2/3 | |||
2 | Rilapladib | Phase 1 |